Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor

To evaluate the effects of the aldose reductase inhibitor Ponalrestat (Statil) on diabetic autonomic neuropathy, a double-blind placebo controlled trial was carried out on a group of 34 diabetic patients with documented cardiac autonomic neuropathy. After a 4-week, placebo run-in period, patients were randomised for treatment with 600 mg Statil or placebo for another 24 weeks. Moreover, the reliability of the autonomic nerve function tests was investigated by comparing the results at onset and at week 4. Fifteen patients treated with Statil and 12 with placebo completed the study. Neither symptom scores nor cardiovascular reflexes, pupil reflexes and skin vasomotor reflexes improved after Statil therapy, which led us to conclude that Statil is not effective in the treatment of diabetic autonomic neuropathy. Reliability coefficients for cardiovascular reflexes and pupil reflex showed high values, ranging from 60% to 80%. Therefore these methods are recommended in future therapy trials.     

中草药醛糖还原酶抑制剂筛选模型的建立

目的：通过观察中药知母对醛糖还原酶活性的抑制作用，建立一种适用于筛选中草药醛糖还原酶抑制剂的模型。方法：大鼠12只随机分成3组：空白对照组、知母组、阳性药物组，分别给予生理盐水、知母水提液、依帕司他水溶液灌胃。采用“通法”给药方案制备含药血清，部分血清经过丙酮预处理。将知母水提液和含药（知母）血清分别加人体外建立的以DL-甘油醛为底物、NADPH为辅酶的醛糖还原酶活性测定体系。结果：丙酮处理过的空白血清较未处理的空白血清对酶活性的影响更小；知母水提液对醛糖还原酶抑制率达99％，含药（知母）血清对醛糖还原酶抑制率达67％。结论：运用血清药理学实验方法建立的筛选模型能有效、可靠的进行中草药醛糖还原酶抑制剂的筛选。     

Axonal transport and tissue contents of substance P in rats with long-term streptozotocin-diabetes. Effects of the aldose reductase inhibitor ‘statil’

This study examined the axonal transport of substance P-like immunoreactivity (SPLI) and its content in dorsal root ganglion, trigeminal ganglion, stomach and ileum of non-diabetic rats and two groups of rats with streptozotocin-induced diabetes of 9 months duration. One diabetic group received the aldose reductase inhibitor ‘Statil’ throughout the period of study. To reduce morbidity all diabetic animals were given twice-weekly injections of a long-acting insulin which restricted weight loss but did not prevent regular and severe hyperglycaemia. Axonal transport of SPLI was studied by measurement of accumulation at 12 h ligatures on the left sciatic nerve. There were no differences between the 3 groups either in the calculated anterograde and retrograde mean rates of accumulation (ranges 6.0 to 7.6 and 0.38 to 0.72 mm/h respectively) or mobile fractions of SPLI (means from 0.54 to 0.58). There were, however, marked reductions in anterograde and retrograde accumulations of SPLI in the constricted nerves of the ‘untreated’ diabetics (respectively 57 and 33% of controls;P < 0.01 for both). In the ‘Statil’-treated rats these deficits were attenuated (80 and 75% of controls). Diabetes also reduced the SPLI content of unligated sciatic nerve and trigeminal ganglion (65 and 75% of controls). ‘Statil’ prevented the deficit in the ganglion, but not in the nerve. ‘Statil’ treatment prevented themyo-inositol depletion and attenuated the sorbitol and fructose accumulation seen in the sciatic nerves of the untreated diabetic animals suggesting effective inhibition of aldose reductase in this tissue. The total SPLI content of the stomach and 1-cm segments of ileum were unaltered in the diabetic animals but due to the increased weights of these tissues the SPLI content per unit weight was reduced. These changes were unaffected by ‘Statil’.     

不同麻醉方法对开胸手术患者红细胞糖代谢限速酶活性的影响

目的 探讨开胸手术患者红细胞内糖代谢限速酶活性的变化及不同麻醉方法对其的影响。方法 48例ASAI～Ⅱ级择期开胸手术患者,按麻醉方式随机分成三组,每组16例。Ⅰ组采用地氟醚吸入为主的全身麻醉;Ⅱ组采用异氟醚吸入为主的全身麻醉;Ⅲ组采用异氟醚吸入联合连续硬膜外阻滞。于麻醉前、手术90min、术后60min及术后第1、2天共五个时点分别测定血糖浓度及红细胞6-磷酸葡萄糖脱氢酶(G-6PD)、磷酸果糖激酶(PFK)和醛糖还原酶(AR)活性。结果 与麻醉前比较,三组患者血糖浓度自术中90min开始,至术后第2天升高显著(P<0.05);Ⅰ、Ⅱ两组术后第1天PFK活性显著下降(P<0.05),G-6PD、AR活性显著升高(P<0.05),而Ⅲ组各时点红细胞内糖代谢限速酶活性的变化与麻醉前比较均无统计学差异(P>0.05),且Ⅲ组术后第1天PFK值远低于Ⅰ组相应值。结论 开胸手术中、手术后存在明显的高血糖反应。术后第1天,红细胞内会出现糖酵解途径受抑制,磷酸戊糖途径、多元醇通路相应活跃现象。采用异氟醚吸入联合硬膜外阻滞可在一定程度上调控手术创伤对红细胞糖代谢的影响。     

Stimulation of nerve growth factor and substance P expression in the iris–trigeminal axis of diabetic rats—involvement of oxidative stress and effects of aldose reductase inhibition

In rats with streptozotocin-induced diabetes, we measured increased (by 61%; P<0.05) mRNA for nerve growth factor (NGF) in the iris together with increased (by 82%; P<0.05) mRNA for preprotachykinin (the substance P precursor) in the trigeminal ganglion, suggesting that increased NGF was driving increased substance P gene expression. In other diabetic rats, these changes were prevented by treatment with either an antioxidant (butylated hydroxytoluene; 1% by diet) or an aldose reductase inhibitor (ARI) (sorbinil; 25 mg/kg/day p.o.) and the sorbinil treatment was associated with significant inhibition of polyol pathway intermediates in both lens and sciatic nerve. This suggests that polyol pathway activity in the lens may translate to oxidative stress-driving stimulation of NGF gene expression in the iris. The change is selective for NGF, because expression of the analogous neurotrophin, neurotrophin-3 (NT-3), was unaltered in the same irises. These changes suggest that oxidative stress and/or inflammation can drive up NGF expression in diabetes—a mechanism that might participate in iritis.     

银染法与放射自显影法检测醛糖还原酶基因多态性的比较

目的 :探讨银染法检测醛糖还原酶 (aldosereductase,AR)基因 5′端微卫星多态性的可靠性。方法 :用银染法和放射自显影法分别检测相同样本DNA的AR基因微卫星多态性 ,比较二者结果。结果 :两种方法均能清楚判读基因型且结果一致。结论 :银染法可以代替放射自显影方法检测AR基因的微卫星多态性     

Vicenin 2 isolated from Artemisia capillaris exhibited potent anti-glycation properties

Vicenin 2, isolated from a traditionally used medicinal plant Artemisia capillaris, is a 6,8-di-C-glucoside of apigenin which has been previously reported to possess a wide variety of pharmacological activities including antioxidant, anti-inflammatory, anti-cancer, and hepatoprotective. However, there have not been any reports concerning its anti-diabetic potential until now. Therefore, in the present study, we evaluated the anti-diabetic potential of vicenin 2 via α-glucosidase, protein tyrosine phosphatase 1B (PTP1B), rat lens aldose reductase (RLAR), and advanced glycation end products (AGE) formation inhibitory assays. Vicenin 2 strongly inhibited α-glucosidase, PTP1B, and RLAR in the corresponding assays. In addition, vicenin 2 inhibited the formation of both fluorescent AGE and nonfluorescent AGE, e.g., CML, as well as the level of fructosamine in glucose–fructose-induced bovine serum albumin (BSA) glycation. In the test system, vicenin 2 suppressed glycation-induced protein oxidation by attenuating the formation of protein carbonyl groups as well as by inhibiting the modification of protein thiol groups. Moreover, vicenin 2 was found to be a potent inhibitor of glycation-induced formation of amyloid cross-β structures in BSA. Taken together, vicenin 2 might be a useful lead for the development of multiple target-oriented therapeutic modalities for the treatment of diabetes and diabetes-associated complications.     

Cyclocarya paliurus extract alleviates diabetic nephropathy by inhibiting oxidative stress and aldose reductase

Diabetes is the leading cause of end-stage renal disease because diabetic nephropathy (DN) develops in 30–40% of the patients. This study investigated the protective effect of the aqueous extract from leaves of Cyclocarya paliurus (Batal.) Iljinsk (ACP) on DN by inhibiting oxidative stress and aldose reductase (AR) activity. ACP was obtained by hot water extraction. The in vitro antioxidant capability and AR inhibition of ACP were investigated by employing various established systems. DN rats were used to assess the reno-protective effect of ACP. Results showed that the polysaccharide and total polyphenol contents of ACP were (479.3?±?19.8) mg/g and (38.3?±?2.3) mg/g, respectively. ACP exhibited strong antioxidant ability and AR inhibition in vitro and in vivo; furthermore, the inhibition mechanism of ACP in AR takes the form of uncompetitive inhibition. In addition, the animals treated with ACP showed significant amelioration of blood glucose, serum biomarkers related to renal function, urinary protein excretion, and histopathological changes in the kidney. The results suggest that ACP has a potential role in ameliorating renal damage involved in DN.     

Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats

Summary Aldose reductase inhibitors (ARIs) attenuate diabetic complications in several tissues, including lens, retina, kidney, blood vessels, striated muscle and peripheral nerve. However, it is unclear whether their action in diabetes mellitus depends directly on inhibiting the conversion of glucose to sorbitol by aldose reductase or indirectly by reducing the sorbitol available for subsequent metabolism to fructose by sorbitol dehydrogenase. To identify the polyol pathway step most relevant to complications, particularly neuropathy, we compared the biochemical effects of a sorbitol dehydrogenase inhibitor, WAY-135 706, (250 mg · kg⁻¹· day⁻¹) and an ARI, WAY-121 509, (10 mg · kg⁻¹· day⁻¹) on a variety of tissues, and their effects on nerve perfusion and conduction velocity. After 6 weeks of untreated streptozotocin diabetes, rats were treated for 2 weeks. Sorbitol was elevated 2.1–32.6-fold by diabetes in lens, retina, kidney, aorta, diaphragm, erythrocytes and sciatic nerve; this was further increased (1.6–8.2-fold) by WAY-135 706 whereas WAY-121 509 caused a marked reduction. Fructose 1.6–8.0-fold elevated by diabetes in tissues other than diaphragm, was reduced by WAY-135 706 and WAY-121 509, except in the kidney. Motor and sensory nerve conduction velocities were decreased by 20.2 and 13.9 %, respectively with diabetes. These deficits were corrected by WAY-121 509, but WAY-135 706 was completely ineffective. A 48.6 % diabetes-induced deficit in sciatic nutritive endoneurial blood flow was corrected by WAY-121 509, but was unaltered by WAY-135 706. Thus, despite profound sorbitol dehydrogenase inhibition, WAY-135 706 had no beneficial effect on nerve function. The data demonstrate that aldose reductase activity, the first step in the polyol pathway, makes a markedly greater contribution to the aetiology of diabetic neurovascular and neurological dysfunction than does the second step involving sorbitol dehydrogenase. [Diabetologia (1997) 40: 271–281] Received: 13 August 1996 and in final revised form: 6 December 1996     

A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy.

The effects of the aldose reductase inhibitor ponalrestat (600 mg day-1) on sensory, electrophysiological, and autonomic function were examined in 50 patients with chronic symptomatic, distal symmetrical diabetic neuropathy in a 52-week randomized, double-blind, parallel-group, placebo-controlled, single-centre study. In an endeavour to identify patients with a degree of neuropathy potentially amenable to pharmacological intervention, a minimum conduction velocity of 30 m s-1 was set for the peroneal motor nerve. At 52 weeks, no significant differences were observed between the ponalrestat and placebo groups in motor (ulnar, median, and peroneal) or sensory (ulnar and radial) nerve conduction velocities, vibration perception thresholds, adjectival symptom scores or tests of autonomic function (mean electrocardiographic R-R interval variability on deep breathing and orthostatic blood pressure response). Ponalrestat was clinically well tolerated and had no significant effect on glycaemic control. The lack of beneficial effects of ponalrestat may in part reflect the advanced stage of the neuropathic process in patients with established symptomatic disease, and the poor reproducibility of current neurophysiological techniques. Firmer knowledge of clinico-pathological correlates allied to improved non-invasive neurophysiological measurement techniques should facilitate the selection of patients for future therapeutic trials in diabetic neuropathy.